Breaking News, Collaborations & Alliances

ONCODESIGN Achieves UCB Milestone

UCB obtains worldwide rights to compounds for neurological disorders

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ONCODESIGN has reached a major milestone in its joint discovery collaboration with UCB relating to its Nanocyclix technology on a kinase target selected by UCB. The collaboration, dating back to October 2013, aims to develop therapies to treat neurological disorders. UCB will now obtain worldwide development and commercialization rights to the compounds. Oncodesign is eligible to receive further research funding, product-related development, regulatory and commercial milestones, as well as royal...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters